Last reviewed · How we verify

Bupivacaine liposome

Tianjin Medical University General Hospital · FDA-approved active Small molecule

Bupivacaine liposome is a long-acting local anesthetic that blocks sodium channels in nerve cell membranes, with the liposomal formulation providing sustained drug release for prolonged anesthesia.

Bupivacaine liposome is a long-acting local anesthetic that blocks sodium channels in nerve cell membranes, with the liposomal formulation providing sustained drug release for prolonged anesthesia. Used for Local anesthesia and analgesia for surgical and post-operative pain management.

At a glance

Generic nameBupivacaine liposome
Also known asQuadratus lumborum block, Exparel, 72 hour Bupivacaine, Long acting Bupivacaine, peripheral nerve block
SponsorTianjin Medical University General Hospital
Drug classLocal anesthetic (liposomal formulation)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine is an amide-type local anesthetic that inhibits sodium influx into nerve cells, preventing depolarization and action potential propagation. The liposomal encapsulation extends the duration of action by providing controlled, sustained release of the drug at the injection site, reducing the frequency of dosing and maintaining anesthetic effect for extended periods.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: